MARKET

MEIP

MEIP

MEI Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.960
+0.020
+1.03%
After Hours: 1.960 0 0.00% 16:00 12/06 EST
OPEN
1.940
PREV CLOSE
1.940
HIGH
1.990
LOW
1.940
VOLUME
240.90K
TURNOVER
--
52 WEEK HIGH
3.410
52 WEEK LOW
1.440
MARKET CAP
144.36M
P/E (TTM)
-26.9972
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MEIP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MEIP News

  • Greenwood Investors Third Quarter 2019 Letter: Long Pubs, Short Tourists
  • Seeking Alpha - Article.11/18 06:52
  • Stocks To Watch: Retailers, Dubai Airshow And Cybertrucks
  • Seeking Alpha - Article.11/16 12:10
  • MEI Pharma to Present at the Stifel 2019 Healthcare Conference
  • PR Newswire.11/12 13:00
  • MEI Pharma EPS beats by $0.13, beats on revenue
  • seekingalpha.11/08 03:10

More

Industry

Biotechnology & Medical Research
+0.66%
Pharmaceuticals & Medical Research
+0.49%

Hot Stocks

Name
Price
%Change

About MEIP

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
More

Webull offers MEI Pharma Inc (MEIP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.